ondasdechoque.org
PT-BR

Neck and trapezius myofascial pain · Randomized trial · 2025

Does adding radial shockwave to exercises help neck and upper-back muscle pain?

With radial shockwave plus exercises and advice, pain fell from about 7 to just under 5 out of 10 by week 12. People who had a sham with the same exercises improved as much or more, to about 3.5.

adults with neck or upper-back muscle pain
70
shockwave sessions, one a week
6
weeks of follow-up
12

Good to know: Both groups did the same exercise programme and got the same advice. About half were seen at week 12; for the others, their last score was used.

Ogbeivor C, AlMubarak H, Akomolafe T, et al. BMC Musculoskeletal Disorders, 2025 · Read the paper ↗

How this study worked

Shockwave + exercise34 peopleSham + exercise36 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

What happened

Neck and upper-back pain

0–10 pain scale · start to week 12

Shockwave + exerciseSham + exercise

Both groups started near 7 out of 10 and improved by week 4. By week 12, pain was just under 5 with shockwave and about 3.5 with sham.
Show the numbers
GroupStartWeek 4Week 8Week 12
Shockwave + exercise6.94.94.74.6
Sham + exercise7.14.74.53.5

The treatment

Shockwave + exercise

Radial, once a week for 6 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
6, one a week
Pulses
2,000 per session
Strength
1.5bar (the paper also gives two different energy values: 0.57 and 0.068 mJ/mm²) · 15 per second
Numbing
Not mentioned
Device
Storz Medical
Everyone also got
Education, stretches and exercises, plus a home exercise plan

Compared with: A low-energy sham (0.3 bar) with the same exercise care

Settings are what each study used, not a prescription.

Who took part

70 adults with neck or upper-back muscle pain and tender trigger points, treated at one outpatient rehabilitation department in Riyadh.

Shockwave + exercise34 people
Sham + exercise36 people

Side effects

Two people in the shockwave group had brief extra tenderness and kept going. The paper also says one person stopped treatment at week 4 because pain increased. No serious side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults aged ≥19 with neck and/or upper-back myofascial pain, palpable tenderness and active trigger point(s), recruited in one Riyadh outpatient rehabilitation department.

Radial shock waves plus shared care34randomized

Authors state ITT with last observation carried forward; 20/70 were lost by week 4. Fig. 1 gives the numbers seen at each visit (shockwave 26, 18 and 15; placebo 23, 12 and 18 at weeks 4, 8 and 12); all 34 and 36 were analysed with carried-forward values.

Low-energy sham plus shared care36randomized

Authors state ITT with last observation carried forward; 20/70 were lost by week 4. Fig. 1 gives the numbers seen at each visit (shockwave 26, 18 and 15; placebo 23, 12 and 18 at weeks 4, 8 and 12); all 34 and 36 were analysed with carried-forward values.

Numeric Pain Score (NPS)3 reported outcomes
01
Week 4

Numeric Pain Score (NPS)

Numeric Pain Score (NPS) points

BaselineFollow-up
Low-energy sham plus shared care
4.7
Radial shock waves plus shared care
4.9
010 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care367.1 (SD 1.4)4.7 (SD 2.6)
Radial shock waves plus shared care346.9 (SD 1.9)4.9 (SD 2.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)-0.27CI 95% -1.6 to 1.05p = 0.681

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-1.9Equal results 01.4

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 26 shockwave and 23 placebo participants followed up at week 4 (the Results text gives 20 of 70 lost by week 4); the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo change 2.4 (SD 0.50) vs shockwave 1.9 (SD 0.44); difference 0.50 (95% CI -0.87 to 1.82), p=0.484. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 2.4 (0.50), 95% CI (1.4, 3.4), p=0.000; shockwave 1.9 (0.44), 95% CI (1.04, 2.8), p=0.000. Tables 4 and 5 print week 0 minus week 4, so positive values mean the pain score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

02
Week 8

Numeric Pain Score (NPS)

Numeric Pain Score (NPS) points

BaselineFollow-up
Low-energy sham plus shared care
4.5
Radial shock waves plus shared care
4.7
010 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care367.1 (SD 1.4)4.5 (SD 2.6)
Radial shock waves plus shared care346.9 (SD 1.9)4.7 (SD 2.8)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)-0.22CI 95% -1.5 to 1.06p = 0.735

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-1.8Equal results 01.4

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 18 shockwave and 12 placebo participants followed up at week 8; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo 2.6 (SD 0.49) vs shockwave 2.2 (SD 0.42); difference 0.40 (95% CI -0.89 to 1.73), p=0.525. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 2.6 (0.49), 95% CI (1.6, 3.6), p=0.000; shockwave 2.1 (0.42), 95% CI (1.3, 3.1), p=0.000. Table 4 reports active-arm change 2.1 (SD 0.42), while Table 5 reports 2.2 (SD 0.42); unresolved table discrepancy. Tables 4 and 5 print week 0 minus week 8, so positive values mean the pain score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

03
Week 12

Numeric Pain Score (NPS)

Numeric Pain Score (NPS) points

BaselineFollow-up
Low-energy sham plus shared care
3.5
Radial shock waves plus shared care
4.6
010 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care367.1 (SD 1.4)3.5 (SD 2.6)
Radial shock waves plus shared care346.9 (SD 1.9)4.6 (SD 2.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)-1.1CI 95% -2.33 to 0.13p = 0.078

Endpoint contrast is nonsignificant. Table 5 separately reports change from baseline: placebo 3.6 (SD 0.49) vs shockwave 2.3 (SD 0.40), difference 1.30 (95% CI 0.017 to 2.59; p=0.047), numerically favoring sham and conflicting with article conclusion.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-2.6Equal results 00.4

No statistically significant pointwise between-group difference at this timepoint.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 15 shockwave and 18 placebo participants followed up at week 12; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo 3.6 (SD 0.49) vs shockwave 2.3 (SD 0.40); difference 1.30 (95% CI 0.017 to 2.59), p=0.047. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 3.6 (0.49), 95% CI (2.6, 4.6), p=0.000; shockwave 2.3 (0.40), 95% CI (1.5, 3.1), p=0.000. Tables 4 and 5 print week 0 minus week 12, so positive values mean the pain score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

Neck Disability Index (NDI)3 reported outcomes
04
Week 4

Neck Disability Index (NDI)

Neck Disability Index (NDI) points

BaselineFollow-up
Low-energy sham plus shared care
24.6
Radial shock waves plus shared care
24.1
050 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3631.1 (SD 15.9)24.6 (SD 16.8)
Radial shock waves plus shared care3429.6 (SD 15.5)24.1 (SD 14)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.5CI 95% -6.9 to 7.91p = 0.892

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-8.7Equal results 09.7

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 26 shockwave and 23 placebo participants followed up at week 4 (the Results text gives 20 of 70 lost by week 4); the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo change 6.47 (SD 2.6) vs shockwave 5.56 (SD 2.1); difference 0.90 (95% CI -5.87 to 7.6), p=0.791. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 6.47 (2.6), 95% CI (1.15, 11.78), p=0.010; shockwave 5.56 (2.1), 95% CI (1.23, 9.90), p=0.010. Tables 4 and 5 print week 0 minus week 4, so positive values mean the disability score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

05
Week 8

Neck Disability Index (NDI)

Neck Disability Index (NDI) points

BaselineFollow-up
Low-energy sham plus shared care
24.9
Radial shock waves plus shared care
24.9
050 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3631.1 (SD 15.9)24.9 (SD 17)
Radial shock waves plus shared care3429.6 (SD 15.5)24.9 (SD 16.6)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.03CI 95% -8 to 8.06p = 0.994

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-9.9Equal results 010

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 18 shockwave and 12 placebo participants followed up at week 8; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo 6.13 (SD 2.7) vs shockwave 4.75 (SD 2.6); difference 1.38 (95% CI -6.2 to 8.96), p=0.718. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 6.13 (2.7), 95% CI (0.56, 11.72), p=0.030; shockwave 4.75 (2.6), 95% CI (− 0.56, 10.07), p=0.070. Tables 4 and 5 print week 0 minus week 8, so positive values mean the disability score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed. The Results text gives p=0.005 for the placebo week 0–8 change, where Table 4 prints p=0.030.

06
Week 12

Neck Disability Index (NDI)

Neck Disability Index (NDI) points

BaselineFollow-up
Low-energy sham plus shared care
22.8
Radial shock waves plus shared care
24.5
050 points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3631.1 (SD 15.9)22.8 (SD 18)
Radial shock waves plus shared care3429.6 (SD 15.5)24.5 (SD 15.7)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)-1.68CI 95% -9.77 to 6.4p = 0.679

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-11.7Equal results 08.3

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 15 shockwave and 18 placebo participants followed up at week 12; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo 8.22 (SD 2.9) vs shockwave 5.12 (SD 2.7); difference 3.09 (95% CI -5.01 to 11.20), p=0.449. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo 8.22 (2.9), 95% CI (2.15, 14.28), p=0.000; shockwave 5.12 (2.7), 95% CI (-.44, 10.69), p=0.060. Tables 4 and 5 print week 0 minus week 12, so positive values mean the disability score fell (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

Pressure pain threshold3 reported outcomes
07
Week 4

Pressure pain threshold

Pressure pain threshold kg/cm²

means
GroupnBaselineFollow-up
Low-energy sham plus shared care362.8 (SD 1.7)3.3 (SD 2.1)
Radial shock waves plus shared care342.4 (SD 1.4)3 (SD 1.3)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.24CI 95% -0.63 to 1.1p = 0.588

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-0.8Equal results 01.3

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 26 shockwave and 23 placebo participants followed up at week 4 (the Results text gives 20 of 70 lost by week 4); the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo change -0.48 (SD 0.21) vs shockwave -0.5 (SD 0.17); difference 0.10 (95% CI -0.46 to 0.66), p=0.718. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 0.48 (0.21), 95% CI (− 0.93, − 0.04), p=0.030; shockwave − 0.5 (0.17), 95% CI (− 0.94, − 0.23), p=0.002. Tables 4 and 5 print week 0 minus week 4, so negative values mean the pressure pain threshold rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed. Table 5 prints a difference of 0.10, although its own group values give about 0.02 (−0.48 minus −0.5); kept as printed.

08
Week 8

Pressure pain threshold

Pressure pain threshold kg/cm²

means
GroupnBaselineFollow-up
Low-energy sham plus shared care362.8 (SD 1.7)3.3 (SD 2.1)
Radial shock waves plus shared care342.4 (SD 1.4)3 (SD 1.4)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.32CI 95% -0.53 to 1.17p = 0.457

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-0.7Equal results 01.4

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 18 shockwave and 12 placebo participants followed up at week 8; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -0.51 (SD 0.21) vs shockwave -0.5 (SD 0.17); difference 0.02 (95% CI -0.55 to 0.58), p=0.951. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 0.51 (0.21), 95% CI (− 0.96, − 0.08), p=0.020; shockwave − 0.5 (0.17), 95% CI (− 0.90, − 0.17), p=0.005. Tables 4 and 5 print week 0 minus week 8, so negative values mean the pressure pain threshold rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

09
Week 12

Pressure pain threshold

Pressure pain threshold kg/cm²

means
GroupnBaselineFollow-up
Low-energy sham plus shared care362.8 (SD 1.7)3.4 (SD 2.1)
Radial shock waves plus shared care342.4 (SD 1.4)3.1 (SD 1.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.314CI 95% -0.57 to 1.2p = 0.479

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-0.8Equal results 01.4

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 15 shockwave and 18 placebo participants followed up at week 12; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -0.66 (SD 0.25) vs shockwave -0.6 (SD 0.17); difference 0.02 (95% CI -0.59 to 0.64), p=0.942. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 0.66 (0.25), 95% CI (− 1.17, − 0.15), p=0.010; shockwave − 0.6 (0.17), 95% CI (− 1.04, − 0.32), p=0.000. Tables 4 and 5 print week 0 minus week 12, so negative values mean the pressure pain threshold rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed. Table 5 prints a difference of 0.02, although its own group values give about −0.06 (−0.66 minus −0.6); kept as printed.

SF-12 Physical Component Score3 reported outcomes
10
Week 4

SF-12 Physical Component Score

SF-12 Physical Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
42.7
Radial shock waves plus shared care
41.8
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3640.9 (SD 9)42.7 (SD 10.8)
Radial shock waves plus shared care3440.8 (SD 8.9)41.8 (SD 7.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.97CI 95% -3.51 to 5.44p = 0.668

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-4.6Equal results 06.5

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 26 shockwave and 23 placebo participants followed up at week 4 (the Results text gives 20 of 70 lost by week 4); the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo change -1.8 (SD 1.1) vs shockwave -0.9 (SD 1.1); difference -0.91 (95% CI -4.1 to 2.31), p=0.5753. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 1.8 (1.1), 95% CI (− 4.24, 0.50), p=0.110; shockwave − 0.9 (1.1), 95% CI (− 3.22, 1.29), p=0.392. Tables 4 and 5 print week 0 minus week 4, so negative values mean the score rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

11
Week 8

SF-12 Physical Component Score

SF-12 Physical Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
43.7
Radial shock waves plus shared care
40.7
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3640.9 (SD 9)43.7 (SD 10.8)
Radial shock waves plus shared care3440.8 (SD 8.9)40.7 (SD 9.1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)2.94CI 95% -1.84 to 7.72p = 0.223

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-3Equal results 08.9

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 18 shockwave and 12 placebo participants followed up at week 8; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -2.8 (SD 1.1) vs shockwave 0.07 (SD 1.4); difference -2.9 (95% CI -6.6 to 0.84); p-value not shown in Table 5. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 2.8 (1.1), 95% CI (− 5.11, − 0.51), p=0.010; shockwave 0.07 (1.4), 95% CI (− 2.97, 3.12), p=0.959. Tables 4 and 5 print week 0 minus week 8, so negative values mean the score rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

12
Week 12

SF-12 Physical Component Score

SF-12 Physical Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
44.3
Radial shock waves plus shared care
42.3
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3640.9 (SD 9)44.3 (SD 9.3)
Radial shock waves plus shared care3440.8 (SD 8.9)42.3 (SD 9.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)1.9CI 95% -2.57 to 6.55p = 0.387

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-3.7Equal results 07.6

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 15 shockwave and 18 placebo participants followed up at week 12; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -3.4 (SD 1.4) vs shockwave -1.40 (SD 1.7); difference -1.93 (95% CI -6.51 to 2.64), p=0.4020. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 3.4 (1.4), 95% CI (− 6.38, − 0.45), p=0.020; shockwave − 1.4 (1.7), 95% CI (− 5.11, 2.15), p=0.412. Tables 4 and 5 print week 0 minus week 12, so negative values mean the score rose (improved). They head the bracketed values SD, but each printed 95% CI spans about twice that value either side of the mean, as expected of a standard error rather than an SD; values are kept as printed.

SF-12 Mental Component Score3 reported outcomes
13
Week 4

SF-12 Mental Component Score

SF-12 Mental Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
47.1
Radial shock waves plus shared care
46.4
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3645.7 (SD 12.2)47.1 (SD 10.9)
Radial shock waves plus shared care3445 (SD 10.6)46.4 (SD 10.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.7CI 95% -4.5 to 5.9p = 0.788

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-5.7Equal results 07.1

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 26 shockwave and 23 placebo participants followed up at week 4 (the Results text gives 20 of 70 lost by week 4); the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo change -1.4 (SD 6.3) vs shockwave -1.42 (SD 8.2); difference 0.01 (95% CI -3.48 to 3.49), p=0.9978. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 1.4 (6.3), 95% CI (− 3.55, 0.70), p=0.183; shockwave − 1.42 (8.2), 95% CI (− 4.30, 1.45), p=0.320. Tables 4 and 5 print week 0 minus week 4, so negative values mean the score rose (improved).

14
Week 8

SF-12 Mental Component Score

SF-12 Mental Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
46.3
Radial shock waves plus shared care
45.3
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3645.7 (SD 12.2)46.3 (SD 11.8)
Radial shock waves plus shared care3445 (SD 10.6)45.3 (SD 9.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.95CI 95% -4.3 to 6.2p = 0.716

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-5.6Equal results 07.5

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 18 shockwave and 12 placebo participants followed up at week 8; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -0.6 (SD 7.5) vs shockwave -0.30 (SD 10.4); difference -0.25 (95% CI -4.58 to 4.09), p=0.9103. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 0.6 (7.5), 95% CI (− 3.17, 1.91), p=0.617; shockwave − 0.3 (10.4), 95% CI (− 4.05, 3.28), p=0.832. Tables 4 and 5 print week 0 minus week 8, so negative values mean the score rose (improved).

15
Week 12

SF-12 Mental Component Score

SF-12 Mental Component Score score points

BaselineFollow-up
Low-energy sham plus shared care
48.4
Radial shock waves plus shared care
47.5
0100 score points
means
GroupnBaselineFollow-up
Low-energy sham plus shared care3645.7 (SD 12.2)48.4 (SD 10.7)
Radial shock waves plus shared care3445 (SD 10.6)47.5 (SD 10.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference (placebo minus shockwave, matching the Table 3 group order)0.89CI 95% -4.2 to 5.9p = 0.726

Between-arm difference at this timepoint; table groups ordered placebo then shockwave.

Unadjusted independent-samples t test. Missing data handled by the authors using ITT with last observation carried forward.

-5.4Equal results 07.1

The reported between-group estimate is nonsignificant and its confidence interval includes zero; this does not establish equivalence.

Analysis details and source

Keep this between-group pointwise contrast distinct from within-arm changes reported in Tables 4 and 5. Fig. 1 reports 15 shockwave and 18 placebo participants followed up at week 12; the analyses kept all 34 and 36 by carrying the last observation forward. Between-arm change-score comparison from Table 5: Placebo -2.7 (SD 8.8) vs shockwave -2.50 (SD 9.7); difference -0.18 (95% CI -4.62 to 4.26), p=0.9354. These change-score tests are separate from Table 3 pointwise comparisons. Within-arm Table 4 change from baseline (not a between-group effect): placebo − 2.7 (8.8), 95% CI (− 5.74, 0.21), p=0.06; shockwave − 2.5 (9.7), 95% CI (− 5.99,.83), p=0.133. Tables 4 and 5 print week 0 minus week 12, so negative values mean the score rose (improved).

How treatment was delivered
Device/modality

Storz Medical radial shock-wave device.

Active energy

Methods report 1.5 bar and 0.57 mJ/mm²; abstract reports 1.5 bar and 0.068 mJ/mm². Unresolved; no conversion applied.

Sham energy

0.3 bar (0.01 mJ/mm²), described as nontherapeutic no-energy shock.

Pulse/frequency/applicator

2,000 pulses/session (stated only in the Abstract, the same Abstract whose energy figure conflicts with the Methods), 15 Hz, D20 transmitter, 20-mm headpiece.

Schedule/target

Six weekly sessions, directly to identified trapezius/periscapular trigger or painful points.

Shared care

Education, stretches, exercises and home-exercise guidance in both arms.

Anesthesia

Not reported.

HARMS & TOLERABILITY

The Results section says one participant discontinued treatment at week 4 because pain increased. The adverse-events section says two active-arm participants had temporary pain sensitivity, neither dropped out, and no adverse-effect dropouts occurred. The report does not clarify whether treatment discontinuation differed from study dropout. The aftercare paragraph says: "Only one participant reported increased pain after the intervention, and no other serious adverse effects were reported in this study."

LIMITS OF THE ANALYSIS

The authors planned 120 participants but enrolled 70; 20/70 (29%) were lost by week 4, and last observation carried forward was used.

Table 5 reports a week-12 NPS change contrast at p=0.047 favoring sham while narrative/conclusion say no between-group difference. Active energy differs between abstract and Methods.

Supplementary Material 1 was cited but unavailable.

The participant flow is internally inconsistent: Results reports 102 approached and 32 excluded (70 randomized), whereas Fig. 1 reports 82 assessed and 10 excluded although its listed reasons sum to 12. At week 4, Fig. 1 shows 26 active plus 23 sham followed (21 not followed), versus Results’ 20/70 lost; later sham counts also rise from 12 at week 8 to 18 at week 12. The figure ends with 34/36 analyzed. The available text does not resolve these discrepancies.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The authors planned 120 participants but enrolled 70; 20/70 (29%) were lost by week 4, and last observation carried forward was used.
  • Table 5 reports a week-12 NPS change contrast at p=0.047 favoring sham while narrative/conclusion say no between-group difference. Active energy differs between abstract and Methods.
  • Supplementary Material 1 was cited but unavailable.
  • The participant flow is internally inconsistent: Results reports 102 approached and 32 excluded (70 randomized), whereas Fig. 1 reports 82 assessed and 10 excluded although its listed reasons sum to 12. At week 4, Fig. 1 shows 26 active plus 23 sham followed (21 not followed), versus Results’ 20/70 lost; later sham counts also rise from 12 at week 8 to 18 at week 12. The figure ends with 34/36 analyzed. The available text does not resolve these discrepancies.
Research review

Source-linked critical reading

Randomized trial with sham / placebo control

Reading depthMaterial consulted
Technical source record

Complete full-text XML, all article sections, Tables 1–5, and the Fig. 1 caption read; Figure 1 was visually inspected and compared with the Results narrative. Supplementary Material 1 was cited but unavailable.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Prospectively registered, two-arm, patient- and assessor-blinded randomized placebo-controlled trial in one Riyadh rehabilitation department. Computer sequence used blocks of four and opaque sealed envelopes; blinded staff collected outcomes and a blinded statistician analyzed results. Seventy participants were randomized, 34 to active treatment and 36 to sham.

Participants

Adults aged at least 19 had neck and/or upper-back pain with palpable tenderness and active trigger points, confirmed by a treating physical therapist. The trial excluded multiple conditions and treatments, including recent trigger-point steroid injection, fibromyalgia, radiculopathy/myelopathy, pregnancy, and recent neck/shoulder surgery. Mean ages were about 45 years; symptom duration averaged roughly 47–51 weeks.

Intervention

The active arm received six radial shock-wave sessions one week apart with a Storz device, 2,000 pulses at 15 Hz, using a 20-mm D20 transmitter over identified trapezius/periscapular trigger or painful points. Methods report 1.5 bar and 0.57 mJ/mm², while the abstract reports 1.5 bar and 0.068 mJ/mm². Both groups also received the same stretches, exercises and home program.

Comparator

The sham group received the same six-session schedule and shared physical therapy, but the device delivered a no-energy shock at 0.3 bar (0.01 mJ/mm²); participants heard the machine. This estimates the incremental effect of a higher-energy radial dose on top of exercise and therapist contact, not ESWT versus no treatment. The abstract/methods report inconsistent active energy values (0.068 versus 0.57 mJ/mm²), which requires source clarification.

Outcomes and follow-up

Primary outcomes were Numeric Pain Score (NPS, 0–10) and Neck Disability Index (NDI, 0–50), assessed at baseline and weeks 4, 8, and 12. Secondary outcomes were pressure pain threshold (PPT) and SF-12 physical and mental scores. The study defined NPS MCID as 2 points or 30%; NDI MCID as 3.5–5 points.

Between-group findings

At week 12, NPS means were 3.5 (SD 2.6) with sham and 4.6 (SD 2.5) with radial shock waves; the endpoint contrast was -1.10 (95% CI -2.33 to 0.13; p=0.078). Table 5 separately reports change from baseline of 3.6 (SD 0.49) with sham versus 2.3 (SD 0.40) with active treatment, difference 1.30 (95% CI 0.017 to 2.59; p=0.047), numerically favoring sham and conflicting with the broader no-difference conclusion. At week 12, between-group endpoint contrasts were nonsignificant for NDI (-1.68; 95% CI -9.77 to 6.40; p=0.679), PPT (0.314 kg/cm²; 95% CI -0.57 to 1.2; p=0.479), SF-12 physical (1.9; 95% CI -2.57 to 6.55; p=0.387) and mental (0.89; 95% CI -4.20 to 5.90; p=0.726). Table 5 does not report a p-value for SF-12 physical change at weeks 0–8. Within-arm changes do not establish superiority.

Harms and tolerability

The report says one participant discontinued treatment at week 4 because pain increased. A later adverse-events paragraph says two active-arm participants had temporary pain sensitivity and neither dropped out; it also says there were no adverse-effect dropouts. The report does not clarify whether “discontinued treatment” differs from study dropout.

Limitations and uncertainty

The trial recruited 70 although its calculation called for 120 to allow for attrition and provide 90% power; 20/70 (29%) were lost by week 4. Missing outcomes were handled with last observation carried forward, which can bias estimates. Most importantly, the report’s conclusion of no between-group difference conflicts with Table 5’s borderline 12-week pain-change result favoring sham; and active energy density differs between the abstract and Methods by nearly an order of magnitude (0.068 vs 0.57 mJ/mm²). The report’s “no adverse-effect dropout” statement also conflicts with the pain-related treatment discontinuation. The participant flow is internally inconsistent: Results reports 102 approached and 32 excluded (70 randomized), whereas Fig. 1 reports 82 assessed and 10 excluded although its listed reasons sum to 12. At week 4, Fig. 1 shows 26 active plus 23 sham followed (21 not followed), versus Results’ 20/70 lost; later sham counts also rise from 12 at week 8 to 18 at week 12. The figure ends with 34/36 analyzed. The available text does not resolve these discrepancies.

Applicability

This pragmatic comparison applies to adults with diagnosed neck/upper-back MPS receiving a substantial shared exercise and therapist-contact program. It does not show that radial shock waves alone are effective. The comparator was a low-energy sham, while the active-dose discrepancy and outcome-reporting conflict weaken confidence in the exact treatment contrast.

What stronger research should do

A transparent replication should reconcile device energy reporting and prespecify whether primary inference uses endpoint or change-score comparisons. It should recruit the planned sample, reduce and characterize follow-up losses, use robust missing-data methods, report blinded between-group estimates and confidence intervals, clarify the pain-related discontinuation, and separate effects of shock waves from shared exercise/contact.

THE ORIGINAL SOURCE

Read the original article.

The effectiveness of radial shockwave therapy on myofascial pain syndrome: a two-armed, randomized double-blind placebo-controlled trial.

Ogbeivor C, AlMubarak H, Akomolafe T, Alkahtani H, AlMugizel H, Marin I, Aldosari H, Aldhwayan N, Mohamed G, Alobthani K. · BMC musculoskeletal disorders · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →